KRAS and non-small cell lung carcinoma: These drugs included TP53 with PC14586 in all solid tumors, EGFR with patritumab deruxtecan in NSCLC, KRAS with trametinib, cobimetinib, and binimetinib in all solid tumors, CDKN2A with abemaciclib, palbociclib, and ribociclib, STK11 with bemcentinib + pembrolizumab, and PIK3CA with RLY-2608 and LOXO-783 in all solid tumors (Table 2).15